Abstract 1397P
Background
Antibody-drug conjugates (ADCs) may extend targeted therapy to patients (pts) whose tumors express an antigen regardless of the presence of a driver mutation. Telisotuzumab vedotin (ABBV-399), a first-in-class MET (or c-Met)-directed ADC, had promising monotherapy anticancer activity in previously treated pts with MET-overexpressing (OE), non-squamous EGFR wild type NSCLC (Camidge et al. JCO. 2022;40:16 suppl, 9016). Characterization of MET OE NSCLC, a novel biomarker-defined therapeutically relevant subgroup, is thus warranted. MET OE was evaluated in a real-world cohort and co-associated with mRNA expression, MET gene amplification (METamp) and mutations, and outcomes to understand prognosis of MET OE NSCLC.
Methods
The cohort comprised treated pts with stage IV NSCLC seeking care at City of Hope National Medical Center in ≥2016 and had tissue adequate for MET immunohistochemistry (IHC). MET OE was determined using anti-MET clone SP44 IHC assay (Roche Tissue Diagnostics; positive if ≥25% cells at 3+ intensity). MET FISH, RNAseq, and whole exome sequencing were conducted. Clinical data were extracted from electronic health records, and unadjusted hazard ratios from 1L treatment initiation until death or censoring were calculated. Pts receiving targeted therapy in 1L were excluded.
Results
84 pts were included; 77% had samples taken prior to metastatic spread. 21 (25%) were MET OE positive. MET OE was not associated with history of smoking. METamp was found in 5/69 tumors evaluated (9%); of these, 2 were MET OE. Only 2 pts had MET mutations; neither were exon 14 skipping and one was MET OE. MET mRNA, evaluated in 58 cases, was 4-fold higher in MET OE NSCLC vs not OE. 1L regimens used were chemotherapy (52.4%), chemotherapy + immune checkpoint inhibitor (ICI; 26.2%), or ICI (21.4%). The unadjusted hazard ratio for death in pts with MET OE NSCLC vs not OE was 2.04 (95% CI: 1.02, 4.10).
Conclusions
Pts with MET OE NSCLC had worse prognosis compared with those without MET OE, when treated with standard of care including ICI. Given the development of MET-directed ADCs, MET OE (distinct from METamp) may be a future target for characterization and treatment of NSCLC.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
AbbVie funded this study and participated in the study design, research, analysis, data collection, interpretation of data, reviewing, and approval of the abstract. All authors had access to relevant data and participated in the drafting, review, and approval of this abstract. No honoraria or payments were made for authorship.
Funding
AbbVie funded this study and participated in the study design, research, analysis, data collection, interpretation of data, reviewing, and approval of the abstract. All authors had access to relevant data and participated in the drafting, review, and approval of this abstract. No honoraria or payments were made for authorship.
Disclosure
J. Bar: Financial Interests, Personal, Advisory Board: AbbVie, AstraZeneca, Bayer, BMS, Causalis, Eisai, MSD, Novartis, Roche, Takeda; Financial Interests, Personal, Research Funding: Immunai, OncoHost, MSD, AstraZeneca. M.H. Cai: Financial Interests, Personal, Stocks/Shares, Employee and may own stock: AbbVie Inc. Y.C. Choi: Financial Interests, Personal, Stocks/Shares, Employee and may own stock: AbbVie Inc. S. Baijal: Financial Interests, Personal, Other, Honoraria: AbbVie, Amgen, AstraZeneca, Boehringer Ingelheim, Bristol Myers Squibb, Chugai, Daiichi Sankyo, Foundation One, Gilead, GSK, Janssen, Lilly, Merck Serono, Merck Sharp & Dohme, Novartis, Pierre Fabre, Pfizer, Roche, Servier, Sanofi, and Takeda. W. Zhao: Financial Interests, Personal, Stocks/Shares, Employee and may own stock: AbbVie Inc. A. Liede: Financial Interests, Personal, Stocks/Shares, Employee and may own stock: AbbVie Inc. L. Raskin: Financial Interests, Personal, Stocks/Shares, Employee and may own stock: AbbVie Inc. A. Vasilopoulos: Financial Interests, Personal, Stocks/Shares, Employee and may own stock: AbbVie Inc. M. Li: Financial Interests, Personal, Stocks/Shares, Employee and may own stock: AbbVie Inc. L. Roberts-Rapp: Financial Interests, Personal, Stocks/Shares, Employee and may own stock: AbbVie Inc.. F. Jiang: Financial Interests, Personal, Stocks/Shares, Employee and may own stock: AbbVie Inc. C. Ratajczak: Financial Interests, Personal, Stocks/Shares, Employee and may own stock: AbbVie Inc. S. Lu: Financial Interests, Personal, Other, Grants or contracts: AstraZeneca, Hutchmed, Bristol Myers Squibb, Hengrui Medicine, BeiGene, Roche, and Hansoh; Financial Interests, Personal, Other, Honoraria for lectures or presentations: AstraZeneca and Hansoh; Financial Interests, Personal, Other, Advisor and consultant: AstraZeneca, Pfizer, Hutchmed, Zai Lab, GenomiCare Biotechnology (Shanghai), Yuhan, Menarini, InventisBio Co., and Roche; Financial Interests, Personal, Other, Data safety monitoring board or advisory board participation: AstraZeneca, Roche, and Mirati Therapeutics. P.J. Ansell: Financial Interests, Personal, Stocks/Shares, Employee and may own stock: AbbVie Inc. D.R. Camidge: Financial Interests, Personal, Advisory Role: AbbVie (steering committee), Amgen, Anheart, Apollomics (SRC), AstraZeneca (SRC/SC), AstraZeneca/Daiichi (ILD adjudication committee), BeiGene (IDMC, DSMB), Bio-Thera (DSMB), Blueprint, Daiichi Sankyo (ILD adjudication committee), Dizal, Elevation (SRC), ; Financial Interests, Personal, Other, Company-sponsored trials at institution (PI roles): AbbVie, AstraZeneca, Blueprint, Dizal, Inhibrx, Karyopharm, Nuvalent, Pfizer, Phosplatin, PsiOxus, Rain, Roche/Genentech, Seattle Genetics, Takeda, Turning Point, Verastem.
Resources from the same session
1423P - Clinical impact of radiological diagnosis of lymphangitic carcinomatosis in patients with extensive non-small cell lung cancer treated with immunotherapy
Presenter: Anita Bolina
Session: Poster session 20
1424P - Outcome of thromboembolic events and its influence on survival time of advanced NSCLC patients receiving antiangiogenic therapy
Presenter: Wei-Fan Ou
Session: Poster session 20
1425P - Clinical utility of liquid biopsy for the early diagnosis of EGFR mutant advanced lung cancer in real-life setting (CLEAR)
Presenter: Rola El Sayed
Session: Poster session 20
1427P - Exploration of the value of leptomeningeal biopsy in diagnosing and treating non-small cell lung cancer with leptomeningeal metastasis
Presenter: Lin Cai
Session: Poster session 20
1428P - Clinical benefit of combination chemo-immunotherapy in first-line treatment for patients over the age of 65 or 75 with metastatic NSCLC
Presenter: Thierry Landre
Session: Poster session 20
1429P - Homologous recombination repair (HRR) gene mutation: A novel biomarker for precision genomics testing in advanced lung cancer
Presenter: Madhu Nagaraj
Session: Poster session 20
1430P - Excellent performance of a fast and fully-automated RNA based genefusion assay conducted on a large fusion positive non-small cell lung cancer cohort within a multicenter study
Presenter: Arndt Hartmann
Session: Poster session 20
1431P - The nNGM Preclinical Platform: Preclinical research to generate evidence for patients with non-small cell lung cancer harboring variants of unknown significance
Presenter: Martin Ziegler
Session: Poster session 20
1432P - Tumor stage shift in lung cancer during the COVID-19 pandemic: A real-world data study of the Network Oncology Registry
Presenter: Anja Thronicke
Session: Poster session 20